MARKET

COLL

COLL

Collegium Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.41
-0.52
-2.27%
Closed 16:00 03/02 EST
OPEN
22.71
PREV CLOSE
22.93
HIGH
23.02
LOW
22.10
VOLUME
377.74K
TURNOVER
--
52 WEEK HIGH
26.91
52 WEEK LOW
13.00
MARKET CAP
778.89M
P/E (TTM)
44.91
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ Collegium Pharmaceutical, Inc. CEO Joe Ciaffoni on Q4 2020 Results -- Earnings Call Transcript >COLL
Dow Jones · 3d ago
Needham Believes Collegium Pharmaceutical (COLL) Still Has Room to Grow
In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL), with a price target of $34.00. The
SmarterAnalyst · 4d ago
Collegium Pharmaceutical EPS misses by $0.11, misses on revenue
Collegium Pharmaceutical (COLL): Q4 GAAP EPS of $0.20 misses by $0.11.Revenue of $76.27M (+2.8% Y/Y) misses by $1.16M.Press Release
Seekingalpha · 5d ago
10-K: COLLEGIUM PHARMACEUTICAL, INC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Collegium Pharmaceutical Q4 EPS $0.20 Misses $0.29 Estimate, Sales $76.27M Miss $77.41M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.29 by 31.03 percent. This is a 385.71 percent increase over losses of $(0.07) per
Benzinga · 5d ago
Collegium Pharmaceutical: Affirms Full-Yr 2021 Fincl Guidance, Initially Provided on Jan 6, 2021 >COLL
Collegium Pharmaceutical: Affirms Full-Yr 2021 Fincl Guidance, Initially Provided on Jan 6, 2021 >COLL
Dow Jones · 5d ago
Collegium Pharmaceutical 4Q EPS 20c >COLL
Collegium Pharmaceutical 4Q EPS 20c >COLL
Dow Jones · 5d ago
Collegium Pharmaceutical 4Q Rev $76.3M >COLL
Collegium Pharmaceutical 4Q Rev $76.3M >COLL
Dow Jones · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of COLL. Analyze the recent business situations of Collegium Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average COLL stock price target is 29.57 with a high estimate of 41.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 249
Institutional Holdings: 39.13M
% Owned: 112.59%
Shares Outstanding: 34.76M
TypeInstitutionsShares
Increased
39
1.31M
New
41
972.23K
Decreased
53
2.12M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.38%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Director
Michael Heffernan
President/Chief Executive Officer/Director
Joseph Ciaffoni
Chief Financial Officer/Executive Vice President
Paul Brannelly
Executive Vice President/Chief Technology Officer
Alison Fleming
Executive Vice President/General Counsel/Secretary
Shirley Kuhlmann
Executive Vice President
Scott Dreyer
Executive Vice President
Richard Malamut
Lead Director/Independent Director
Gino Santini
Director
Rita Balice-Gordon
Independent Director
Garen Bohlin
Independent Director
John Fallon
Independent Director
John Freund
Independent Director
Gwen Melincoff
Independent Director
Theodore Schroeder
  • Dividends
  • Splits
  • Insider Activity
No Data
About COLL
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Webull offers kinds of Collegium Pharmaceutical Inc stock information, including NASDAQ:COLL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COLL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading COLL stock methods without spending real money on the virtual paper trading platform.